30 closest matches · ranked by relevance
Benign Prostatic Hyperplasia
Primary: Qmax Assessed Using Urodynamic Testing (Cystometry) — 14.0 mL/sec
Prostate Cancer
Primary: Number of Participants With Clinically Significant Cancer — 38; 31 Participants
Nephrectomy
Primary: Safety of the Bitrack System — 0; 0 adverse events
Urinary Incontinence
Primary: Self-reported Urinary Incontinence, Irritative and Obstructive Symptoms: Reduction of 70%+ in the Urogenital Distress Inventory From Baseline to 12 Mos and "Very Much"…
Urostomy
Primary: Preference of Sensura vs Moderma — 45; 43 percentage of prefering the product
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day
Nephrolithiasis
Primary: Change in Kidney Injury Molecule-1 (KIM-1) — 0.01077; 0.01228; 0.0246; 0.02413 ng/ml
Post-operative Urinary Retention
Primary: Number of Patients Who Undergo Postoperative Catheterization for Urinary Retention — 23; 25 Participants — p=.96
Ureterolithiases
Primary: Proportion of Patients Passing Their Stone Within 28 Days by Self Report — 128; 113 Participants
Circulatory; Change
Primary: Peak Systolic Velocities (PSV) Measurement by Renal Doppler Ultrasound (US) Examination Evaluating the Effects of Flexible Ureteroscopy (F-URS) on Renal Blood Flow by…
Healthy
Primary: Voided Volume — 306 mL
Inguinal Hernia
Primary: Number of Participants With Post Operative Urinary Retention — 23; 21 Participants
Prostate Cancer · Cancer of the PROSTATE · Prostatic Neoplasm
Primary: Keyword Description of Each Biopsy Sample — 89 percentage significant cancers detected
Ureteral Obstruction
Primary: Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion — 1.76; 1.84; 2.02; 1.93 score on a scale
Benign Prostatic Hyperplasia
Primary: Quality of Recovery — 28; 16 participants
Lower Urinary Tract Symptoms
Primary: Change in Urinary Nerve Growth Factor (pg/mL) at Baseline Compared to Post Dose Exposure at Mo.3/Wk12 — -10.9 pg/ml
Urinary Tract Diseases
Primary: Total Opioid Consumption — 16.4; 15.3 morphine equivalent
Benign Prostatic Hyperplasia (BPH)
Primary: Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment — 45.5 percentage
Carcinoma, Transitional Cell · Transitional Cell Carcinoma of Renal Pelvis
Primary: The Primary Efficacy Endpoint Was the Number of Patients Attaining Complete Response (CR) at the End of the Treatment Period (PDE Visit). — 42 Participants
Disorder of Urinary Stent
Primary: Lower Urinary Tract Symptoms (LUTS) — 11.12; 4.39; 7.21; 5.58 units on a scale
Renal Stone · Nephrolithiasis · Urolithiasis
Primary: Number of Participants With Successful Sheath Placement — 37; 39 Participants
Urinary Retention
Primary: Number of Participants Who Achieved Post-void Residual (PVR) of ≤150 ml Over 90 Days — 79 Participants
Ureteral Calculi
Primary: Number of Participants With Stone Expulsion — 39; 40 Participants
Ureteral Calculi
Primary: Time in Days From Diagnosis to Stone Passage. — 5; 13 Days
Benign Prostatic Hyperplasia
Primary: Responder Analysis: A Subject is a Responder at the 12 Month Follow-up Time Point if All 6 Thresholds of the BPH-6 Endpoint Are Met — 52; 20 % Responders of Participants
Benign Prostatic Hyperplasia
Primary: The Percentage of Men Given a Drug Prescription for Their Urinary Symptoms, as Recorded in Their Medical Records — 35.7 Percentage of participants
Acute Urinary Retention · Benign Prostatic Hyperplasia
Primary: Successful Trial Without Catheter Peri-procedurally — 29; 0 Participants
Lower Urinary Tract Symptoms · Overactive Bladder
Primary: Number of Participants Reporting Downward/Flat/Upward Patterns as Assessed by Near Infrared Spectroscopy (NIRS) for BOO Diagnosis — 9; 4; 13; 4 participants
Urinary Lithiasis · Kidney Diseases · Kidney Stone
Primary: Post-operative Pain — 22; 30 milligram morphine equivalent
Kidney Calculi · Ureter Calculi
Primary: Overall Procedure Time — 64.5; 54.1 minutes